ID   RIPK1_HUMAN             Reviewed;         671 AA.
AC   Q13546; A0AV89; B2RAG1; B4E3F9; Q13180; Q59H33;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 3.
DT   12-OCT-2022, entry version 227.
DE   RecName: Full=Receptor-interacting serine/threonine-protein kinase 1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133};
DE   AltName: Full=Cell death protein RIP {ECO:0000303|PubMed:8612133};
DE   AltName: Full=Receptor-interacting protein 1 {ECO:0000303|PubMed:16603398};
DE            Short=RIP-1 {ECO:0000303|PubMed:16603398};
GN   Name=RIPK1 {ECO:0000312|HGNC:HGNC:10019};
GN   Synonyms=RIP {ECO:0000303|PubMed:8612133}, RIP1
GN   {ECO:0000303|PubMed:16603398};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-45, INTERACTION WITH TRADD; TRAF1;
RP   TRAF2 AND TRAF3, AND VARIANT VAL-438.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=8612133; DOI=10.1016/s1074-7613(00)80252-6;
RA   Hsu H., Huang J., Shu H.-B., Baichwal V.R., Goeddel D.V.;
RT   "TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1
RT   signaling complex.";
RL   Immunity 4:387-396(1996).
RN   [2]
RP   SEQUENCE REVISION TO 120.
RA   Huang J., Hsu H., Baichwal V.R., Goeddel D.V.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 15-671 (ISOFORM 2).
RC   TISSUE=Adrenal gland, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-234.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-438.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-671.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 300-671, AND VARIANT VAL-438.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1;
RA   Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;
RT   "RIP: a novel protein containing a death domain that interacts with
RT   Fas/APO-1 (CD95) in yeast and causes cell death.";
RL   Cell 81:513-523(1995).
RN   [9]
RP   INTERACTION WITH CRADD, AND DOMAIN.
RX   PubMed=9044836;
RA   Ahmad M., Srinivasula S.M., Wang L., Talanian R.V., Litwack G.,
RA   Fernandes-Alnemri T., Alnemri E.S.;
RT   "CRADD, a novel human apoptotic adaptor molecule for caspase-2, and
RT   FasL/tumor necrosis factor receptor-interacting protein RIP.";
RL   Cancer Res. 57:615-619(1997).
RN   [10]
RP   CLEAVAGE BY CASP8, AND MUTAGENESIS OF ASP-324.
RX   PubMed=10521396; DOI=10.1101/gad.13.19.2514;
RA   Lin Y., Devin A., Rodriguez Y., Liu Z.-G.;
RT   "Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced
RT   apoptosis.";
RL   Genes Dev. 13:2514-2526(1999).
RN   [11]
RP   INTERACTION WITH SQSTM1 AND TRAF2, AND DOMAIN DEATH.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [12]
RP   INTERACTION WITH RIPK3.
RX   PubMed=10358032; DOI=10.1074/jbc.274.24.16871;
RA   Sun X., Lee J., Navas T., Baldwin D.T., Stewart T.A., Dixit V.M.;
RT   "RIP3, a novel apoptosis-inducing kinase.";
RL   J. Biol. Chem. 274:16871-16875(1999).
RN   [13]
RP   INTERACTION WITH BNLF1.
RX   PubMed=10409763; DOI=10.1128/mcb.19.8.5759;
RA   Izumi K.M., Cahir McFarland E., Ting A.T., Riley E.A., Seed B., Kieff E.D.;
RT   "The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the
RT   tumor necrosis factor receptor-associated proteins TRADD and receptor-
RT   interacting protein (RIP) but does not induce apoptosis or require RIP for
RT   NF-kappaB activation.";
RL   Mol. Cell. Biol. 19:5759-5767(1999).
RN   [14]
RP   INTERACTION WITH IKBKG.
RX   PubMed=9927690; DOI=10.1073/pnas.96.3.1042;
RA   Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A.,
RA   Wallach D., Horwitz M.S.;
RT   "Identification of a cell protein (FIP-3) as a modulator of NF-kappaB
RT   activity and as a target of an adenovirus inhibitor of tumor necrosis
RT   factor alpha-induced apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1042-1047(1999).
RN   [15]
RP   FUNCTION.
RX   PubMed=11101870; DOI=10.1038/82732;
RA   Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S.,
RA   Bodmer J.L., Schneider P., Seed B., Tschopp J.;
RT   "Fas triggers an alternative, caspase-8-independent cell death pathway
RT   using the kinase RIP as effector molecule.";
RL   Nat. Immunol. 1:489-495(2000).
RN   [16]
RP   INTERACTION WITH EGFR.
RX   PubMed=11116146; DOI=10.1074/jbc.m008458200;
RA   Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S.,
RA   Vartanian T.;
RT   "The epidermal growth factor receptor engages receptor interacting protein
RT   and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-
RT   kappa B. Identification of a novel receptor-tyrosine kinase signalosome.";
RL   J. Biol. Chem. 276:8865-8874(2001).
RN   [17]
RP   INTERACTION WITH RNF216.
RX   PubMed=11854271; DOI=10.1074/jbc.m108675200;
RA   Chen D., Li X., Zhai Z., Shu H.-B.;
RT   "A novel zinc finger protein interacts with receptor-interacting protein
RT   (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B
RT   activation.";
RL   J. Biol. Chem. 277:15985-15991(2002).
RN   [18]
RP   RIP HOMOTYPIC INTERACTION MOTIF, AND INTERACTION WITH RIPK3.
RX   PubMed=11734559; DOI=10.1074/jbc.m109488200;
RA   Sun X., Yin J., Starovasnik M.A., Fairbrother W.J., Dixit V.M.;
RT   "Identification of a novel homotypic interaction motif required for the
RT   phosphorylation of receptor-interacting protein (RIP) by RIP3.";
RL   J. Biol. Chem. 277:9505-9511(2002).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-384, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [20]
RP   INTERACTION WITH ZFAND5.
RX   PubMed=14754897; DOI=10.1074/jbc.m309491200;
RA   Huang J., Teng L., Li L., Liu T., Li L., Chen D., Xu L.-G., Zhai Z.,
RA   Shu H.-B.;
RT   "ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor of
RT   NFkappaB activation.";
RL   J. Biol. Chem. 279:16847-16853(2004).
RN   [21]
RP   INTERACTION WITH DAB2IP.
RX   PubMed=15310755; DOI=10.1074/jbc.m407617200;
RA   Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W.;
RT   "AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-
RT   induced ASK1-JNK activation.";
RL   J. Biol. Chem. 279:44955-44965(2004).
RN   [22]
RP   UBIQUITINATION BY TRAF2, AND DEUBIQUITINATION BY TNFAIP3.
RX   PubMed=15258597; DOI=10.1038/nature02794;
RA   Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S.,
RA   Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M.;
RT   "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-
RT   kappaB signalling.";
RL   Nature 430:694-699(2004).
RN   [23]
RP   INTERACTION WITH MAVS.
RX   PubMed=16127453; DOI=10.1038/ni1243;
RA   Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J.,
RA   Takeuchi O., Akira S.;
RT   "IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon
RT   induction.";
RL   Nat. Immunol. 6:981-988(2005).
RN   [24]
RP   UBIQUITINATION AT LYS-377, AND MUTAGENESIS OF LYS-377.
RX   PubMed=16603398; DOI=10.1016/j.molcel.2006.03.026;
RA   Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J.;
RT   "Activation of IKK by TNFalpha requires site-specific ubiquitination of
RT   RIP1 and polyubiquitin binding by NEMO.";
RL   Mol. Cell 22:245-257(2006).
RN   [25]
RP   REVIEW.
RX   PubMed=17301840; DOI=10.1038/sj.cdd.4402085;
RA   Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P.;
RT   "RIP1, a kinase on the crossroads of a cell's decision to live or die.";
RL   Cell Death Differ. 14:400-410(2007).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF DAB2IP, AND INTERACTION WITH DAB2IP.
RX   PubMed=17389591; DOI=10.1074/jbc.m701148200;
RA   Zhang H., Zhang H., Lin Y., Li J., Pober J.S., Min W.;
RT   "RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical
RT   for tumor necrosis factor-induced ASK1-JNK/p38 activation.";
RL   J. Biol. Chem. 282:14788-14796(2007).
RN   [27]
RP   INTERACTION WITH RBCK1.
RX   PubMed=17449468; DOI=10.1074/jbc.m701913200;
RA   Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P., Zhang M.,
RA   Chen D.Y., Zhai Z.H., Shu H.B.;
RT   "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-
RT   triggered NF-kappaB activation by targeting TAB2/3 for degradation.";
RL   J. Biol. Chem. 282:16776-16782(2007).
RN   [28]
RP   INTERACTION WITH RFFL, AND UBIQUITINATION BY RFFL.
RX   PubMed=18450452; DOI=10.1016/j.cub.2008.04.017;
RA   Liao W., Xiao Q., Tchikov V., Fujita K., Yang W., Wincovitch S.,
RA   Garfield S., Conze D., El-Deiry W.S., Schuetze S., Srinivasula S.M.;
RT   "CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates
RT   TNF-induced NF-kappaB activation.";
RL   Curr. Biol. 18:641-649(2008).
RN   [29]
RP   MUTAGENESIS OF SER-161, INHIBITION BY NECROSTATIN-1, AND PHOSPHORYLATION AT
RP   SER-6; SER-20; SER-25; SER-161; SER-166; SER-303; SER-320 AND SER-333.
RX   PubMed=18408713; DOI=10.1038/nchembio.83;
RA   Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X.,
RA   Abbott D., Cuny G.D., Yuan C., Wagner G., Hedrick S.M., Gerber S.A.,
RA   Lugovskoy A., Yuan J.;
RT   "Identification of RIP1 kinase as a specific cellular target of
RT   necrostatins.";
RL   Nat. Chem. Biol. 4:313-321(2008).
RN   [30]
RP   INTERACTION WITH MURID HERPESVIRUS 1 PROTEIN RIR1.
RX   PubMed=18442983; DOI=10.1074/jbc.c800051200;
RA   Upton J.W., Kaiser W.J., Mocarski E.S.;
RT   "Cytomegalovirus M45 cell death suppression requires receptor-interacting
RT   protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with
RT   RIP1.";
RL   J. Biol. Chem. 283:16966-16970(2008).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [32]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=19524513; DOI=10.1016/j.cell.2009.05.037;
RA   Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M.,
RA   Chan F.K.;
RT   "Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates
RT   programmed necrosis and virus-induced inflammation.";
RL   Cell 137:1112-1123(2009).
RN   [33]
RP   FUNCTION, AND INTERACTION WITH RIPK3.
RX   PubMed=19524512; DOI=10.1016/j.cell.2009.05.021;
RA   He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X.;
RT   "Receptor interacting protein kinase-3 determines cellular necrotic
RT   response to TNF-alpha.";
RL   Cell 137:1100-1111(2009).
RN   [34]
RP   INTERACTION WITH RNF34, AND UBIQUITINATION BY RNF34.
RX   DOI=10.1016/j.cub.2008.11.041;
RA   Liao W., Fujita K., Xiao Q., Tchikov V., Yang W., Gunsor M., Garfield S.,
RA   Goldsmith P., El-Deiry W.S., Schuetze S., Srinivasula S.M.;
RT   "Response: CARP1 regulates induction of NF-kappaB by TNFalpha.";
RL   Curr. Biol. 19:R17-R19(2009).
RN   [35]
RP   REVIEW.
RX   PubMed=20354226; DOI=10.1126/scisignal.3115re4;
RA   Vandenabeele P., Declercq W., Van Herreweghe F., Vanden Berghe T.;
RT   "The role of the kinases RIP1 and RIP3 in TNF-induced necrosis.";
RL   Sci. Signal. 3:RE4-RE4(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   UBIQUITINATION BY THE LUBAC COMPLEX.
RX   PubMed=21455173; DOI=10.1038/nature09816;
RA   Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E.,
RA   Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W., Nachbur U.,
RA   Gangoda L., Warnken U., Purcell A.W., Silke J., Walczak H.;
RT   "Linear ubiquitination prevents inflammation and regulates immune
RT   signalling.";
RL   Nature 471:591-596(2011).
RN   [38]
RP   UBIQUITINATION BY BIRC2/C-IAP1 AND BIRC3/C-IAP2, AND INTERACTION WITH
RP   BIRC2/C-IAP1; BIRC3/C-IAP2 AND XIAP/BIRC4.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J.,
RA   Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [39]
RP   IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK3 AND MLKL.
RX   PubMed=22265414; DOI=10.1016/j.cell.2011.11.030;
RA   Wang Z., Jiang H., Chen S., Du F., Wang X.;
RT   "The mitochondrial phosphatase PGAM5 functions at the convergence point of
RT   multiple necrotic death pathways.";
RL   Cell 148:228-243(2012).
RN   [40]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=21887730; DOI=10.1002/ibd.21851;
RA   Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B.,
RA   Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.;
RT   "Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1.";
RL   Inflamm. Bowel Dis. 18:603-612(2012).
RN   [41]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=22858542; DOI=10.1038/cdd.2012.98;
RA   van Raam B.J., Ehrnhoefer D.E., Hayden M.R., Salvesen G.S.;
RT   "Intrinsic cleavage of receptor-interacting protein kinase-1 by
RT   caspase-6.";
RL   Cell Death Differ. 20:86-96(2013).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   GLYCOSYLATION AT ARG-603 (MICROBIAL INFECTION).
RX   PubMed=23955153; DOI=10.1038/nature12436;
RA   Li S., Zhang L., Yao Q., Li L., Dong N., Rong J., Gao W., Ding X., Sun L.,
RA   Chen X., Chen S., Shao F.;
RT   "Pathogen blocks host death receptor signalling by arginine GlcNAcylation
RT   of death domains.";
RL   Nature 501:242-246(2013).
RN   [44]
RP   INTERACTION WITH TNFRSF1A.
RX   PubMed=24130170; DOI=10.1093/carcin/bgt338;
RA   Kim T.W., Kang Y.K., Park Z.Y., Kim Y.H., Hong S.W., Oh S.J., Sohn H.A.,
RA   Yang S.J., Jang Y.J., Lee D.C., Kim S.Y., Yoo H.S., Kim E., Yeom Y.I.,
RA   Park K.C.;
RT   "SH3RF2 functions as an oncogene by mediating PAK4 protein stability.";
RL   Carcinogenesis 35:624-634(2014).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [46]
RP   REVIEW.
RX   PubMed=25459879; DOI=10.1016/j.molcel.2014.11.001;
RA   Weinlich R., Green D.R.;
RT   "The two faces of receptor interacting protein kinase-1.";
RL   Mol. Cell 56:469-480(2014).
RN   [47]
RP   INTERACTION WITH TICAM1.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [48]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 AND 2 PROTEIN RIR1 (MICROBIAL
RP   INFECTION).
RX   PubMed=25674983; DOI=10.1016/j.chom.2015.01.003;
RA   Guo H., Omoto S., Harris P.A., Finger J.N., Bertin J., Gough P.J.,
RA   Kaiser W.J., Mocarski E.S.;
RT   "Herpes simplex virus suppresses necroptosis in human cells.";
RL   Cell Host Microbe 17:243-251(2015).
RN   [49]
RP   INTERACTION WITH MUMPS VIRUS PROTEIN SH (MICROBIAL INFECTION).
RX   PubMed=28659487; DOI=10.1128/jvi.01037-17;
RA   Franz S., Rennert P., Woznik M., Gruetzke J., Luedde A., Arriero Pais E.M.,
RA   Finsterbusch T., Geyer H., Mankertz A., Friedrich N.;
RT   "Mumps virus SH protein inhibits NF-kappaB activation by interacting with
RT   tumor necrosis factor receptor 1, interleukin-1 receptor 1, and Toll-like
RT   receptor 3 complexes.";
RL   J. Virol. 91:0-0(2017).
RN   [50]
RP   INTERACTION WITH PELI1 AND RIPK3, AND UBIQUITINATION BY PELI1.
RX   PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016;
RA   Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K.,
RA   Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.;
RT   "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent
RT   proteasomal degradation.";
RL   Mol. Cell 70:920-935(2018).
RN   [51]
RP   FUNCTION, SUBUNIT, MUTAGENESIS OF LYS-599, AND PHOSPHORYLATION AT SER-166.
RX   PubMed=29440439; DOI=10.1073/pnas.1722013115;
RA   Meng H., Liu Z., Li X., Wang H., Jin T., Wu G., Shan B.,
RA   Christofferson D.E., Qi C., Yu Q., Li Y., Yuan J.;
RT   "Death-domain dimerization-mediated activation of RIPK1 controls
RT   necroptosis and RIPK1-dependent apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E2001-E2009(2018).
RN   [52]
RP   INVOLVEMENT IN IMD57.
RX   PubMed=30026316; DOI=10.1126/science.aar2641;
RA   Cuchet-Lourenco D., Eletto D., Wu C., Plagnol V., Papapietro O., Curtis J.,
RA   Ceron-Gutierrez L., Bacon C.M., Hackett S., Alsaleem B., Maes M.,
RA   Gaspar M., Alisaac A., Goss E., AlIdrissi E., Siegmund D., Wajant H.,
RA   Kumararatne D., AlZahrani M.S., Arkwright P.D., Abinun M., Doffinger R.,
RA   Nejentsev S.;
RT   "Biallelic RIPK1 mutations in humans cause severe immunodeficiency,
RT   arthritis, and intestinal inflammation.";
RL   Science 361:810-813(2018).
RN   [53]
RP   REVIEW.
RX   PubMed=31457011; DOI=10.3389/fcell.2019.00163;
RA   Ang R.L., Chan M., Ting A.T.;
RT   "Ripoptocide - A Spark for Inflammation.";
RL   Front. Cell Dev. Biol. 7:163-163(2019).
RN   [54]
RP   FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-25, AND MUTAGENESIS OF
RP   SER-25 AND LYS-45.
RX   PubMed=30988283; DOI=10.1038/s41467-019-09690-0;
RA   Dondelinger Y., Delanghe T., Priem D., Wynosky-Dolfi M.A., Sorobetea D.,
RA   Rojas-Rivera D., Giansanti P., Roelandt R., Gropengiesser J.,
RA   Ruckdeschel K., Savvides S.N., Heck A.J.R., Vandenabeele P., Brodsky I.E.,
RA   Bertrand M.J.M.;
RT   "Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in
RT   models of infection and inflammation.";
RL   Nat. Commun. 10:1729-1729(2019).
RN   [55]
RP   FUNCTION, PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), AND MUTAGENESIS OF
RP   539-ILE--GLY-542.
RX   PubMed=32657447; DOI=10.15252/embj.2020104469;
RA   Ashida H., Sasakawa C., Suzuki T.;
RT   "A unique bacterial tactic to circumvent the cell death crosstalk induced
RT   by blockade of caspase-8.";
RL   EMBO J. 39:e104469-e104469(2020).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-294 IN COMPLEXES WITH
RP   NECROSTATIN-TYPE INHIBITORS, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=23473668; DOI=10.1016/j.str.2013.01.016;
RA   Xie T., Peng W., Liu Y., Yan C., Maki J., Degterev A., Yuan J., Shi Y.;
RT   "Structural basis of RIP1 inhibition by necrostatins.";
RL   Structure 21:493-499(2013).
RN   [57] {ECO:0007744|PDB:5V7Z}
RP   STRUCTURE BY NMR OF 532-549 IN COMPLEX WITH RIPK3, SUBUNIT, INTERACTION
RP   WITH RIPK3, DOMAIN, AND MUTAGENESIS OF SER-536.
RX   PubMed=29681455; DOI=10.1016/j.cell.2018.03.032;
RA   Mompean M., Li W., Li J., Laage S., Siemer A.B., Bozkurt G., Wu H.,
RA   McDermott A.E.;
RT   "The structure of the necrosome RIPK1-RIPK3 core, a human hetero-amyloid
RT   signaling complex.";
RL   Cell 173:1244-1253(2018).
RN   [58] {ECO:0007744|PDB:6AC5}
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 561-671, GLYCOSYLATION AT ARG-603
RP   (MICROBIAL INFECTION), AND MUTAGENESIS OF ARG-603.
RX   PubMed=30979585; DOI=10.1016/j.molcel.2019.03.028;
RA   Ding J., Pan X., Du L., Yao Q., Xue J., Yao H., Wang D.C., Li S., Shao F.;
RT   "Structural and functional insights into host death domains inactivation by
RT   the bacterial arginine GlcNAcyltransferase effector.";
RL   Mol. Cell 74:922-935(2019).
RN   [59]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-64; ILE-81; VAL-220; SER-404; VAL-443
RP   AND VAL-569.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [60]
RP   INVOLVEMENT IN AIEFL, VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324,
RP   CHARACTERIZATION OF VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324, CLEAVAGE
RP   BY CASP8, AND FUNCTION.
RX   PubMed=31827281; DOI=10.1038/s41586-019-1828-5;
RA   Lalaoui N., Boyden S.E., Oda H., Wood G.M., Stone D.L., Chau D., Liu L.,
RA   Stoffels M., Kratina T., Lawlor K.E., Zaal K.J.M., Hoffmann P.M.,
RA   Etemadi N., Shield-Artin K., Biben C., Tsai W.L., Blake M.D., Kuehn H.S.,
RA   Yang D., Anderton H., Silke N., Wachsmuth L., Zheng L., Moura N.S.,
RA   Beck D.B., Gutierrez-Cruz G., Ombrello A.K., Pinto-Patarroyo G.P.,
RA   Kueh A.J., Herold M.J., Hall C., Wang H., Chae J.J., Dmitrieva N.I.,
RA   McKenzie M., Light A., Barham B.K., Jones A., Romeo T.M., Zhou Q.,
RA   Aksentijevich I., Mullikin J.C., Gross A.J., Shum A.K., Hawkins E.D.,
RA   Masters S.L., Lenardo M.J., Boehm M., Rosenzweig S.D., Pasparakis M.,
RA   Voss A.K., Gadina M., Kastner D.L., Silke J.;
RT   "Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory
RT   disease.";
RL   Nature 577:103-108(2020).
RN   [61]
RP   INVOLVEMENT IN AIEFL, VARIANTS AIEFL HIS-324 AND VAL-324, CHARACTERIZATION
RP   OF VARIANTS AIEFL HIS-324 AND VAL-324, FUNCTION, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, PHOSPHORYLATION AT SER-166, AND CLEAVAGE BY CASP8.
RX   PubMed=31827280; DOI=10.1038/s41586-019-1830-y;
RA   Tao P., Sun J., Wu Z., Wang S., Wang J., Li W., Pan H., Bai R., Zhang J.,
RA   Wang Y., Lee P.Y., Ying W., Zhou Q., Hou J., Wang W., Sun B., Yang M.,
RA   Liu D., Fang R., Han H., Yang Z., Huang X., Li H., Deuitch N., Zhang Y.,
RA   Dissanayake D., Haude K., McWalter K., Roadhouse C., MacKenzie J.J.,
RA   Laxer R.M., Aksentijevich I., Yu X., Wang X., Yuan J., Zhou Q.;
RT   "A dominant autoinflammatory disease caused by non-cleavable variants of
RT   RIPK1.";
RL   Nature 577:109-114(2020).
CC   -!- FUNCTION: Serine-threonine kinase which is a key regulator of TNF-
CC       mediated apoptosis, necroptosis and inflammatory pathways
CC       (PubMed:32657447, PubMed:31827280, PubMed:31827281). Exhibits kinase
CC       activity-dependent functions that regulate cell death and kinase-
CC       independent scaffold functions regulating inflammatory signaling and
CC       cell survival (PubMed:11101870, PubMed:19524512, PubMed:19524513,
CC       PubMed:29440439, PubMed:30988283). Has kinase-independent scaffold
CC       functions: upon binding of TNF to TNFR1, RIPK1 is recruited to the TNF-
CC       R1 signaling complex (TNF-RSC also known as complex I) where it acts as
CC       a scaffold protein promoting cell survival, in part, by activating the
CC       canonical NF-kappa-B pathway (By similarity). Kinase activity is
CC       essential to regulate necroptosis and apoptosis, two parallel forms of
CC       cell death: upon activation of its protein kinase activity, regulates
CC       assembly of two death-inducing complexes, namely complex IIa (RIPK1-
CC       FADD-CASP8), which drives apoptosis, and the complex IIb (RIPK1-RIPK3-
CC       MLKL), which drives necroptosis (By similarity). RIPK1 is required to
CC       limit CASP8-dependent TNFR1-induced apoptosis (By similarity). In
CC       normal conditions, RIPK1 acts as an inhibitor of RIPK3-dependent
CC       necroptosis, a process mediated by RIPK3 component of complex IIb,
CC       which catalyzes phosphorylation of MLKL upon induction by ZBP1
CC       (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283).
CC       Inhibits RIPK3-mediated necroptosis via FADD-mediated recruitment of
CC       CASP8, which cleaves RIPK1 and limits TNF-induced necroptosis
CC       (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283).
CC       Required to inhibit apoptosis and necroptosis during embryonic
CC       development: acts by preventing the interaction of TRADD with FADD
CC       thereby limiting aberrant activation of CASP8 (By similarity). In
CC       addition to apoptosis and necroptosis, also involved in inflammatory
CC       response by promoting transcriptional production of pro-inflammatory
CC       cytokines, such as interleukin-6 (IL6) (PubMed:31827280,
CC       PubMed:31827281). Phosphorylates RIPK3: RIPK1 and RIPK3 undergo
CC       reciprocal auto- and trans-phosphorylation (PubMed:19524513).
CC       Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and
CC       thereby activates the MAP3K5-JNK apoptotic cascade (PubMed:17389591,
CC       PubMed:15310755). Required for ZBP1-induced NF-kappa-B activation in
CC       response to DNA damage (By similarity). {ECO:0000250|UniProtKB:Q60855,
CC       ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:15310755,
CC       ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:19524512,
CC       ECO:0000269|PubMed:19524513, ECO:0000269|PubMed:29440439,
CC       ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280,
CC       ECO:0000269|PubMed:31827281, ECO:0000269|PubMed:32657447}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283,
CC         ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:23473668,
CC         ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280,
CC         ECO:0000269|PubMed:8612133};
CC   -!- ACTIVITY REGULATION: Serine-threonine kinase activity is inhibited by
CC       linear polyubiquitination ('Met-1'-linked) by the LUBAC complex (By
CC       similarity). Inhibited by necrostatins, including necrostatin-1,
CC       necrostatin-3 and necrostatin-4 (PubMed:23473668).
CC       {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:23473668}.
CC   -!- SUBUNIT: Homodimer (PubMed:29440439, PubMed:29681455). Interacts (via
CC       RIP homotypic interaction motif) with RIPK3 (via RIP homotypic
CC       interaction motif); this interaction induces RIPK1 phosphorylation and
CC       formation of a RIPK1-RIPK3 necroptosis-inducing complex
CC       (PubMed:11734559, PubMed:29883609, PubMed:19524512, PubMed:10358032,
CC       PubMed:29681455). Upon TNF-induced necrosis, the RIPK1-RIPK3 dimer
CC       further interacts with PGAM5 and MLKL; the formation of this complex
CC       leads to PGAM5 phosphorylation and increase in PGAM5 phosphatase
CC       activity (PubMed:22265414). Interacts (via the death domain) with
CC       TNFRSF6 (via the death domain) and TRADD (via the death domain)
CC       (PubMed:8612133). Is recruited by TRADD to TNFRSF1A in a TNF-dependent
CC       process (PubMed:24130170). Binds RNF216, EGFR, IKBKG, TRAF1, TRAF2 and
CC       TRAF3 (PubMed:8612133, PubMed:9927690, PubMed:11854271,
CC       PubMed:11116146). Interacts with BNLF1 (PubMed:10409763). Interacts
CC       with SQSTM1 upon TNF-alpha stimulation (PubMed:10356400). May interact
CC       with MAVS/IPS1 (PubMed:16127453). Interacts with ZFAND5
CC       (PubMed:14754897). Interacts with RBCK1 (PubMed:17449468). Interacts
CC       with ZBP1 (By similarity). Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2
CC       and XIAP/BIRC4 (PubMed:21931591). Interacts (via kinase domain) with
CC       DAB2IP (via Ras-GAP domain); the interaction occurs in a TNF-alpha-
CC       dependent manner (PubMed:17389591, PubMed:15310755). Interacts with
CC       ARHGEF2 (PubMed:21887730). Interacts (via protein kinase domain) with
CC       RFFL; involved in RIPK1 ubiquitination (PubMed:18450452). Interacts
CC       with RNF34; involved in RIPK1 ubiquitination (Ref.34). Interacts with
CC       TICAM1 and this interaction is enhanced in the presence of WDFY1
CC       (PubMed:25736436). Interacts with PELI1 (PubMed:29883609). Interacts
CC       (via death domain) with CRADD (via death domain); the interaction is
CC       direct (PubMed:9044836). Component of complex IIa composed of at least
CC       RIPK1, FADD and CASP8 (By similarity). Component of the AIM2
CC       PANoptosome complex, a multiprotein complex that drives inflammatory
CC       cell death (PANoptosis) (By similarity). Interacts with MAP3K7, CFLAR,
CC       CASP8, FADD and NEMO (By similarity). {ECO:0000250|UniProtKB:Q60855,
CC       ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10358032,
CC       ECO:0000269|PubMed:10409763, ECO:0000269|PubMed:11116146,
CC       ECO:0000269|PubMed:11734559, ECO:0000269|PubMed:11854271,
CC       ECO:0000269|PubMed:14754897, ECO:0000269|PubMed:16127453,
CC       ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17449468,
CC       ECO:0000269|PubMed:18450452, ECO:0000269|PubMed:19524512,
CC       ECO:0000269|PubMed:21887730, ECO:0000269|PubMed:21931591,
CC       ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:24130170,
CC       ECO:0000269|PubMed:25736436, ECO:0000269|PubMed:29440439,
CC       ECO:0000269|PubMed:29681455, ECO:0000269|PubMed:29883609,
CC       ECO:0000269|PubMed:8612133, ECO:0000269|PubMed:9044836,
CC       ECO:0000269|PubMed:9927690, ECO:0000269|Ref.34}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein SH;
CC       this interaction inhibits downstream NF-kappa-B pathway activation.
CC       {ECO:0000269|PubMed:28659487}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Murid herpesvirus 1
CC       protein RIR1. {ECO:0000269|PubMed:18442983}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction
CC       motif) with herpes simplex virus 1/HHV-1 protein RIR1/ICP6 (via RIP
CC       homotypic interaction motif); this interaction prevents necroptosis
CC       activation. {ECO:0000269|PubMed:25674983}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction
CC       motif) with herpes simplex virus 2/HHV-2 protein RIR1/ICP10 (via RIP
CC       homotypic interaction motif); this interaction prevents necroptosis
CC       activation. {ECO:0000269|PubMed:25674983}.
CC   -!- INTERACTION:
CC       Q13546; P04083: ANXA1; NbExp=5; IntAct=EBI-358507, EBI-354007;
CC       Q13546; Q13490: BIRC2; NbExp=5; IntAct=EBI-358507, EBI-514538;
CC       Q13546; Q13489: BIRC3; NbExp=3; IntAct=EBI-358507, EBI-517709;
CC       Q13546; Q92851: CASP10; NbExp=2; IntAct=EBI-358507, EBI-495095;
CC       Q13546; Q14790: CASP8; NbExp=28; IntAct=EBI-358507, EBI-78060;
CC       Q13546; Q8IVM0: CCDC50; NbExp=2; IntAct=EBI-358507, EBI-723996;
CC       Q13546; P48729: CSNK1A1; NbExp=5; IntAct=EBI-358507, EBI-1383726;
CC       Q13546; Q13158: FADD; NbExp=11; IntAct=EBI-358507, EBI-494804;
CC       Q13546; Q9Y6K9: IKBKG; NbExp=8; IntAct=EBI-358507, EBI-81279;
CC       Q13546; Q9ULZ3: PYCARD; NbExp=2; IntAct=EBI-358507, EBI-751215;
CC       Q13546; Q13546: RIPK1; NbExp=10; IntAct=EBI-358507, EBI-358507;
CC       Q13546; Q9Y572: RIPK3; NbExp=26; IntAct=EBI-358507, EBI-298250;
CC       Q13546; P19438: TNFRSF1A; NbExp=6; IntAct=EBI-358507, EBI-299451;
CC       Q13546; Q13077: TRAF1; NbExp=6; IntAct=EBI-358507, EBI-359224;
CC       Q13546; Q12933: TRAF2; NbExp=8; IntAct=EBI-358507, EBI-355744;
CC       Q13546; Q13114: TRAF3; NbExp=3; IntAct=EBI-358507, EBI-357631;
CC       Q13546; Q13107: USP4; NbExp=4; IntAct=EBI-358507, EBI-723290;
CC       Q13546; B7UI21: nleB1; Xeno; NbExp=4; IntAct=EBI-358507, EBI-16070376;
CC       Q13546; PRO_0000449629 [P0DTD1]: rep; Xeno; NbExp=5; IntAct=EBI-358507, EBI-25475885;
CC       Q13546; U5TQE9: UL39; Xeno; NbExp=3; IntAct=EBI-358507, EBI-11894787;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q60855}. Cell
CC       membrane {ECO:0000250|UniProtKB:Q9ZUF4}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13546-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13546-2; Sequence=VSP_037690;
CC   -!- DOMAIN: The RIP homotypic interaction motif (RHIM) mediates interaction
CC       with the RHIM motif of RIPK1. Both motifs form a hetero-amyloid
CC       serpentine fold, stabilized by hydrophobic packing and featuring an
CC       unusual Cys-Ser ladder of alternating Ser (from RIPK1) and Cys (from
CC       RIPK3). {ECO:0000269|PubMed:29681455}.
CC   -!- DOMAIN: The death domain mediates dimerization and activation of its
CC       kinase activity during necroptosis and apoptosis (PubMed:29440439). It
CC       engages other DD-containing proteins as well as a central
CC       (intermediate) region important for NF-kB activation and RHIM-dependent
CC       signaling (PubMed:10356400). {ECO:0000269|PubMed:10356400,
CC       ECO:0000269|PubMed:29440439}.
CC   -!- PTM: (Microbial infection) Proteolytically cleaved by S.flexneri OspD3
CC       within the RIP homotypic interaction motif (RHIM), leading to its
CC       degradation and inhibition of necroptosis.
CC       {ECO:0000269|PubMed:32657447}.
CC   -!- PTM: Proteolytically cleaved by CASP8 at Asp-324 (PubMed:10521396,
CC       PubMed:31827281, PubMed:31827280). Cleavage is crucial for limiting
CC       TNF-induced apoptosis, necroptosis and inflammatory response
CC       (PubMed:31827281, PubMed:31827280). Cleavage abolishes NF-kappa-B
CC       activation and enhances the interaction of TRADD with FADD
CC       (PubMed:10521396). Proteolytically cleaved by CASP6 during intrinsic
CC       apoptosis (PubMed:22858542). {ECO:0000250|UniProtKB:Q60855,
CC       ECO:0000269|PubMed:10521396, ECO:0000269|PubMed:31827280,
CC       ECO:0000269|PubMed:31827281}.
CC   -!- PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation
CC       (PubMed:18408713, PubMed:19524513, PubMed:31827280). Phosphorylation of
CC       Ser-161 by RIPK3 is necessary for the formation of the necroptosis-
CC       inducing complex (PubMed:18408713). Phosphorylation at Ser-25 represses
CC       its kinase activity and consequently prevents TNF-mediated RIPK1-
CC       dependent cell death (PubMed:30988283). Phosphorylated at Ser-320 by
CC       MAP3K7 which requires prior ubiquitination with 'Lys-63'-linked chains
CC       by BIRC2/c-IAP1 and BIRC3/c-IAP2 (By similarity). This phosphorylation
CC       positively regulates RIPK1 interaction with RIPK3 to promote
CC       necroptosis but negatively regulates RIPK1 kinase activity and its
CC       interaction with FADD to mediate apoptosis (By similarity).
CC       {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:18408713,
CC       ECO:0000269|PubMed:19524513, ECO:0000269|PubMed:30988283,
CC       ECO:0000269|PubMed:31827280}.
CC   -!- PTM: Ubiquitinated with 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear-
CC       linked type ubiquitin (PubMed:15258597, PubMed:16603398,
CC       PubMed:18450452, PubMed:21455173, PubMed:21931591, PubMed:29883609,
CC       Ref.34). Polyubiquitination with 'Lys-63'-linked chains by TRAF2
CC       induces association with the IKK complex (PubMed:15258597).
CC       Deubiquitination of 'Lys-63'-linked chains and polyubiquitination with
CC       'Lys-48'-linked chains by TNFAIP3 leads to RIPK1 proteasomal
CC       degradation and consequently down-regulates TNF-alpha-induced NF-kappa-
CC       B signaling (PubMed:15258597). 'Lys-48'-linked polyubiquitination by
CC       RFFL or RNF34 also promotes proteasomal degradation and negatively
CC       regulates TNF-alpha-induced NF-kappa-B signaling (PubMed:18450452,
CC       Ref.34). Linear polyubiquitinated; the head-to-tail linear
CC       polyubiquitination ('Met-1'-linked) is mediated by the LUBAC complex
CC       and decreases protein kinase activity (PubMed:21455173).
CC       Deubiquitination of linear polyubiquitin by CYLD promotes the kinase
CC       activity (By similarity). Polyubiquitinated with 'Lys-48' and 'Lys-63'-
CC       linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation
CC       of NF-kappa-B (PubMed:21931591). Ubiquitinated with 'Lys-63'-linked
CC       chains by PELI1 (PubMed:29883609). Ubiquitination at Lys-377 with 'Lys-
CC       63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2 is essential for its
CC       phosphorylation at Ser-320 mediated by MAP3K7 (By similarity). This
CC       ubiquitination is required for NF-kB activation, suppresses RIPK1
CC       kinase activity and plays a critical role in preventing cell death
CC       during embryonic development (By similarity).
CC       {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:15258597,
CC       ECO:0000269|PubMed:16603398, ECO:0000269|PubMed:18450452,
CC       ECO:0000269|PubMed:21455173, ECO:0000269|PubMed:21931591,
CC       ECO:0000269|PubMed:29883609, ECO:0000269|Ref.34}.
CC   -!- PTM: (Microbial infection) Glycosylated at Arg-603 by enteropathogenic
CC       E.coli protein NleB1: arginine GlcNAcylation prevents
CC       homotypic/heterotypic death domain interactions.
CC       {ECO:0000305|PubMed:23955153}.
CC   -!- DISEASE: Immunodeficiency 57 with autoinflammation (IMD57)
CC       [MIM:618108]: An autosomal recessive primary immunodeficiency
CC       characterized by lymphopenia and recurrent viral, bacterial, and fungal
CC       infections. Patients exhibit early-onset inflammatory bowel disease
CC       involving the upper and lower gastrointestinal tract, and develop
CC       progressive polyarthritis. {ECO:0000269|PubMed:30026316}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. RIPK1-deficient immune cells from IMD57 patients have impaired
CC       proinflammatory signaling leading to dysregulated cytokine secretion
CC       and are prone to necroptosis. {ECO:0000269|PubMed:30026316}.
CC   -!- DISEASE: Autoinflammation with episodic fever and lymphadenopathy
CC       (AIEFL) [MIM:618852]: An autosomal dominant immunologic disorder
CC       characterized by early onset of recurrent episodes of unexplained
CC       fever, lymphadenopathy, hepatosplenomegaly, and increased levels of
CC       inflammatory cytokines and chemokines in patient serum.
CC       {ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG65471.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ripk1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U50062; AAC32232.1; -; mRNA.
DR   EMBL; AK314176; BAG36858.1; -; mRNA.
DR   EMBL; AK304701; BAG65471.1; ALT_INIT; mRNA.
DR   EMBL; AY682848; AAT74626.1; -; Genomic_DNA.
DR   EMBL; AL031963; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC126254; AAI26255.1; -; mRNA.
DR   EMBL; BC126256; AAI26257.1; -; mRNA.
DR   EMBL; AB208926; BAD92163.1; -; mRNA.
DR   EMBL; U25994; AAC50137.1; -; mRNA.
DR   CCDS; CCDS4482.1; -. [Q13546-1]
DR   PIR; T09479; T09479.
DR   RefSeq; NP_003795.2; NM_003804.4. [Q13546-1]
DR   RefSeq; XP_005249514.2; XM_005249457.3.
DR   PDB; 4ITH; X-ray; 2.25 A; A/B=1-294.
DR   PDB; 4ITI; X-ray; 2.86 A; A/B=1-294.
DR   PDB; 4ITJ; X-ray; 1.80 A; A/B=1-294.
DR   PDB; 4NEU; X-ray; 2.57 A; A/B=1-324.
DR   PDB; 5HX6; X-ray; 2.23 A; A/B=1-294.
DR   PDB; 5TX5; X-ray; 2.56 A; A/B=1-294.
DR   PDB; 5V7Z; NMR; -; B/D/F/H=532-549.
DR   PDB; 6AC5; X-ray; 1.45 A; A=561-671.
DR   PDB; 6C3E; X-ray; 2.60 A; A/B=2-294.
DR   PDB; 6C4D; X-ray; 2.52 A; A/B/C/D=2-294.
DR   PDB; 6HHO; X-ray; 3.49 A; A/B=1-294.
DR   PDB; 6NW2; X-ray; 2.00 A; A/B=1-294.
DR   PDB; 6NYH; X-ray; 2.10 A; A/B=1-294.
DR   PDB; 6OCQ; X-ray; 2.79 A; A/B=1-294.
DR   PDB; 6R5F; X-ray; 3.25 A; A/B/C/D=1-294.
DR   PDB; 6RLN; X-ray; 2.87 A; A/B=1-294.
DR   PDB; 7CJB; X-ray; 2.80 A; D/H/L/P=189-203.
DR   PDB; 7FCZ; X-ray; 2.21 A; A/B=1-294.
DR   PDB; 7FD0; X-ray; 2.00 A; A/B=1-294.
DR   PDBsum; 4ITH; -.
DR   PDBsum; 4ITI; -.
DR   PDBsum; 4ITJ; -.
DR   PDBsum; 4NEU; -.
DR   PDBsum; 5HX6; -.
DR   PDBsum; 5TX5; -.
DR   PDBsum; 5V7Z; -.
DR   PDBsum; 6AC5; -.
DR   PDBsum; 6C3E; -.
DR   PDBsum; 6C4D; -.
DR   PDBsum; 6HHO; -.
DR   PDBsum; 6NW2; -.
DR   PDBsum; 6NYH; -.
DR   PDBsum; 6OCQ; -.
DR   PDBsum; 6R5F; -.
DR   PDBsum; 6RLN; -.
DR   PDBsum; 7CJB; -.
DR   PDBsum; 7FCZ; -.
DR   PDBsum; 7FD0; -.
DR   AlphaFoldDB; Q13546; -.
DR   BMRB; Q13546; -.
DR   SMR; Q13546; -.
DR   BioGRID; 114274; 166.
DR   ComplexPortal; CPX-1907; Ripoptosome.
DR   CORUM; Q13546; -.
DR   DIP; DIP-433N; -.
DR   IntAct; Q13546; 93.
DR   MINT; Q13546; -.
DR   STRING; 9606.ENSP00000259808; -.
DR   BindingDB; Q13546; -.
DR   ChEMBL; CHEMBL5464; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13546; -.
DR   GuidetoPHARMACOLOGY; 2189; -.
DR   GlyGen; Q13546; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q13546; -.
DR   MetOSite; Q13546; -.
DR   PhosphoSitePlus; Q13546; -.
DR   BioMuta; RIPK1; -.
DR   DMDM; 60393639; -.
DR   CPTAC; CPTAC-1053; -.
DR   CPTAC; CPTAC-900; -.
DR   CPTAC; CPTAC-901; -.
DR   CPTAC; CPTAC-902; -.
DR   EPD; Q13546; -.
DR   jPOST; Q13546; -.
DR   MassIVE; Q13546; -.
DR   MaxQB; Q13546; -.
DR   PaxDb; Q13546; -.
DR   PeptideAtlas; Q13546; -.
DR   PRIDE; Q13546; -.
DR   ProteomicsDB; 59527; -. [Q13546-1]
DR   ProteomicsDB; 59528; -. [Q13546-2]
DR   Antibodypedia; 4145; 652 antibodies from 42 providers.
DR   DNASU; 8737; -.
DR   Ensembl; ENST00000259808.9; ENSP00000259808.3; ENSG00000137275.16. [Q13546-1]
DR   Ensembl; ENST00000380409.3; ENSP00000369773.3; ENSG00000137275.16. [Q13546-2]
DR   GeneID; 8737; -.
DR   KEGG; hsa:8737; -.
DR   MANE-Select; ENST00000259808.9; ENSP00000259808.3; NM_001354930.2; NP_001341859.1.
DR   UCSC; uc003mux.4; human. [Q13546-1]
DR   CTD; 8737; -.
DR   DisGeNET; 8737; -.
DR   GeneCards; RIPK1; -.
DR   HGNC; HGNC:10019; RIPK1.
DR   HPA; ENSG00000137275; Low tissue specificity.
DR   MalaCards; RIPK1; -.
DR   MIM; 603453; gene.
DR   MIM; 618108; phenotype.
DR   MIM; 618852; phenotype.
DR   neXtProt; NX_Q13546; -.
DR   OpenTargets; ENSG00000137275; -.
DR   Orphanet; 529977; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome.
DR   PharmGKB; PA34394; -.
DR   VEuPathDB; HostDB:ENSG00000137275; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   GeneTree; ENSGT00940000159347; -.
DR   HOGENOM; CLU_017229_0_0_1; -.
DR   InParanoid; Q13546; -.
DR   OrthoDB; 346354at2759; -.
DR   PhylomeDB; Q13546; -.
DR   TreeFam; TF106506; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q13546; -.
DR   Reactome; R-HSA-140534; Caspase activation via Death Receptors in the presence of ligand.
DR   Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-2562578; TRIF-mediated programmed cell death.
DR   Reactome; R-HSA-3295583; TRP channels.
DR   Reactome; R-HSA-3371378; Regulation by c-FLIP.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5218900; CASP8 activity is inhibited.
DR   Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-69416; Dimerization of procaspase-8.
DR   Reactome; R-HSA-75893; TNF signaling.
DR   Reactome; R-HSA-9013957; TLR3-mediated TICAM1-dependent programmed cell death.
DR   Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-9686347; Microbial modulation of RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-9693928; Defective RIPK1-mediated regulated necrosis.
DR   SignaLink; Q13546; -.
DR   SIGNOR; Q13546; -.
DR   BioGRID-ORCS; 8737; 35 hits in 1120 CRISPR screens.
DR   ChiTaRS; RIPK1; human.
DR   GeneWiki; RIPK1; -.
DR   GenomeRNAi; 8737; -.
DR   Pharos; Q13546; Tchem.
DR   PRO; PR:Q13546; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q13546; protein.
DR   Bgee; ENSG00000137275; Expressed in granulocyte and 152 other tissues.
DR   ExpressionAtlas; Q13546; baseline and differential.
DR   Genevisible; Q13546; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031264; C:death-inducing signaling complex; IDA:BHF-UCL.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0097342; C:ripoptosome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0070513; F:death domain binding; IPI:BHF-UCL.
DR   GO; GO:0005123; F:death receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:1990000; P:amyloid fibril formation; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0008219; P:cell death; IMP:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISS:ARUK-UCL.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0070266; P:necroptotic process; IMP:UniProtKB.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0060546; P:negative regulation of necroptotic process; ISS:UniProtKB.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:1905206; P:positive regulation of hydrogen peroxide-induced cell death; IMP:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:0070105; P:positive regulation of interleukin-6-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; IMP:UniProtKB.
DR   GO; GO:1903800; P:positive regulation of miRNA maturation; IDA:ARUK-UCL.
DR   GO; GO:0060545; P:positive regulation of necroptotic process; IMP:UniProtKB.
DR   GO; GO:0010940; P:positive regulation of necrotic cell death; IMP:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; TAS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:BHF-UCL.
DR   GO; GO:1903265; P:positive regulation of tumor necrosis factor-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0097300; P:programmed necrotic cell death; ISS:ARUK-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030163; P:protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0070926; P:regulation of ATP:ADP antiporter activity; IMP:BHF-UCL.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0097343; P:ripoptosome assembly; IMP:UniProtKB.
DR   GO; GO:1901026; P:ripoptosome assembly involved in necroptotic process; IEA:Ensembl.
DR   GO; GO:0070231; P:T cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IC:BHF-UCL.
DR   CDD; cd08777; Death_RIP1; 1.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR025735; RHIM_dom.
DR   InterPro; IPR037934; RIP1_Death.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF12721; RHIM; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane;
KW   Cytoplasm; Disease variant; Glycoprotein; Host-virus interaction;
KW   Inflammatory response; Isopeptide bond; Kinase; Membrane; Necrosis;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..671
FT                   /note="Receptor-interacting serine/threonine-protein kinase
FT                   1"
FT                   /id="PRO_0000086606"
FT   DOMAIN          17..289
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          583..669
FT                   /note="Death"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00064"
FT   REGION          290..582
FT                   /note="Interaction with SQSTM1"
FT                   /evidence="ECO:0000269|PubMed:10356400"
FT   REGION          331..354
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          389..458
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           531..547
FT                   /note="RIP homotypic interaction motif (RHIM)"
FT                   /evidence="ECO:0000269|PubMed:11734559,
FT                   ECO:0000269|PubMed:29681455"
FT   COMPBIAS        331..346
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        403..420
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        423..458
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        138
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         23..31
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         45
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            324..325
FT                   /note="Cleavage; by CASP8"
FT                   /evidence="ECO:0000269|PubMed:10521396,
FT                   ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281"
FT   MOD_RES         6
FT                   /note="Phosphoserine; by IKKA and IKKB"
FT                   /evidence="ECO:0000269|PubMed:18408713"
FT   MOD_RES         20
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         25
FT                   /note="Phosphoserine; by IKKA and IKKB"
FT                   /evidence="ECO:0000269|PubMed:18408713,
FT                   ECO:0000269|PubMed:30988283"
FT   MOD_RES         161
FT                   /note="Phosphoserine; by RIPK3 and autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         166
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:29440439,
FT                   ECO:0000269|PubMed:31827280"
FT   MOD_RES         303
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18408713"
FT   MOD_RES         320
FT                   /note="Phosphoserine; by MAP3K7"
FT                   /evidence="ECO:0000269|PubMed:18408713,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         331
FT                   /note="Phosphoserine; by MAP3K7"
FT                   /evidence="ECO:0000250|UniProtKB:Q60855"
FT   MOD_RES         333
FT                   /note="Phosphoserine; by MAP3K7"
FT                   /evidence="ECO:0000269|PubMed:18408713"
FT   MOD_RES         384
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15144186"
FT   CARBOHYD        603
FT                   /note="(Microbial infection) N-beta-linked (GlcNAc)
FT                   arginine"
FT                   /evidence="ECO:0000269|PubMed:30979585,
FT                   ECO:0000305|PubMed:23955153, ECO:0007744|PDB:6AC5"
FT   CROSSLNK        377
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:16603398"
FT   VAR_SEQ         108..153
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037690"
FT   VARIANT         64
FT                   /note="A -> V (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs774996232)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041039"
FT   VARIANT         81
FT                   /note="V -> I (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs758268804)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041040"
FT   VARIANT         220
FT                   /note="A -> V (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs759012409)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041041"
FT   VARIANT         234
FT                   /note="E -> K (in dbSNP:rs17548383)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_021109"
FT   VARIANT         324
FT                   /note="D -> H (in AIEFL; prevents cleavage by CASP8;
FT                   increased kinase activity; increased inflammatory
FT                   response)"
FT                   /evidence="ECO:0000269|PubMed:31827280,
FT                   ECO:0000269|PubMed:31827281"
FT                   /id="VAR_083518"
FT   VARIANT         324
FT                   /note="D -> N (in AIEFL; prevents cleavage by CASP8;
FT                   changed inflammatory response)"
FT                   /evidence="ECO:0000269|PubMed:31827281"
FT                   /id="VAR_083519"
FT   VARIANT         324
FT                   /note="D -> V (in AIEFL; prevents cleavage by CASP8;
FT                   increased kinase activity; increased inflammatory
FT                   response)"
FT                   /evidence="ECO:0000269|PubMed:31827280"
FT                   /id="VAR_084135"
FT   VARIANT         324
FT                   /note="D -> Y (in AIEFL; prevents cleavage by CASP8;
FT                   changed inflammatory response)"
FT                   /evidence="ECO:0000269|PubMed:31827281"
FT                   /id="VAR_083520"
FT   VARIANT         404
FT                   /note="A -> S (in dbSNP:rs34872409)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041042"
FT   VARIANT         438
FT                   /note="A -> V (in dbSNP:rs3173519)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7538908, ECO:0000269|PubMed:8612133"
FT                   /id="VAR_058285"
FT   VARIANT         443
FT                   /note="A -> V (in dbSNP:rs35722193)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041043"
FT   VARIANT         569
FT                   /note="A -> V (in dbSNP:rs55861377)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041044"
FT   MUTAGEN         25
FT                   /note="S->D: Phophomimetic mutant. Significant loss of
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:30988283"
FT   MUTAGEN         45
FT                   /note="K->A: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:30988283,
FT                   ECO:0000269|PubMed:8612133"
FT   MUTAGEN         161
FT                   /note="S->A: Decreases RIPK1 kinase activity."
FT                   /evidence="ECO:0000269|PubMed:18408713"
FT   MUTAGEN         161
FT                   /note="S->E: No effect on RIPK1 autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:18408713"
FT   MUTAGEN         324
FT                   /note="D->K: Abolishes cleavage by caspase-8."
FT                   /evidence="ECO:0000269|PubMed:10521396"
FT   MUTAGEN         377
FT                   /note="K->R: Abolishes RIP-mediated NF-Kappa-B activation."
FT                   /evidence="ECO:0000269|PubMed:16603398"
FT   MUTAGEN         536
FT                   /note="S->C: Strongly reduced homodimerization and
FT                   interaction with RIPK3."
FT                   /evidence="ECO:0000269|PubMed:29681455"
FT   MUTAGEN         539..542
FT                   /note="IQIG->AAAA: Abolished cleavage by S.flexneri OspD3."
FT                   /evidence="ECO:0000269|PubMed:32657447"
FT   MUTAGEN         599
FT                   /note="K->R: Blocks homodimerization, necroptosis and
FT                   apoptosis."
FT                   /evidence="ECO:0000269|PubMed:29440439"
FT   MUTAGEN         603
FT                   /note="R->A: Abolished GlcNAcylation by E.coli NleB1."
FT                   /evidence="ECO:0000269|PubMed:30979585"
FT   CONFLICT        258
FT                   /note="R -> I (in Ref. 3; BAG36858)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        286
FT                   /note="R -> S (in Ref. 3; BAG36858)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        514
FT                   /note="T -> S (in Ref. 8; AAC50137)"
FT                   /evidence="ECO:0000305"
FT   STRAND          10..12
FT                   /evidence="ECO:0007829|PDB:7FD0"
FT   HELIX           14..16
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          17..19
FT                   /evidence="ECO:0007829|PDB:5HX6"
FT   STRAND          20..22
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          26..28
FT                   /evidence="ECO:0007829|PDB:7FD0"
FT   STRAND          30..36
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   TURN            37..39
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          40..51
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           54..56
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           57..68
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          78..84
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          87..93
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           100..104
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          106..108
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           112..131
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           141..143
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          144..146
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           163..168
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:4ITH"
FT   HELIX           190..192
FT                   /evidence="ECO:0007829|PDB:6NW2"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           207..223
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           228..230
FT                   /evidence="ECO:0007829|PDB:6C4D"
FT   HELIX           234..242
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           249..251
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   TURN            252..255
FT                   /evidence="ECO:0007829|PDB:6C3E"
FT   HELIX           258..267
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           272..274
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           278..292
FT                   /evidence="ECO:0007829|PDB:4ITJ"
FT   HELIX           294..296
FT                   /evidence="ECO:0007829|PDB:4NEU"
FT   HELIX           297..309
FT                   /evidence="ECO:0007829|PDB:4NEU"
FT   TURN            310..312
FT                   /evidence="ECO:0007829|PDB:4NEU"
FT   STRAND          533..542
FT                   /evidence="ECO:0007829|PDB:5V7Z"
FT   HELIX           575..577
FT                   /evidence="ECO:0007829|PDB:6AC5"
FT   HELIX           584..593
FT                   /evidence="ECO:0007829|PDB:6AC5"
FT   HELIX           599..604
FT                   /evidence="ECO:0007829|PDB:6AC5"
FT   HELIX           609..618
FT                   /evidence="ECO:0007829|PDB:6AC5"
FT   TURN            619..622
FT                   /evidence="ECO:0007829|PDB:6AC5"
FT   HELIX           624..643
FT                   /evidence="ECO:0007829|PDB:6AC5"
FT   HELIX           646..655
FT                   /evidence="ECO:0007829|PDB:6AC5"
FT   HELIX           659..668
FT                   /evidence="ECO:0007829|PDB:6AC5"
SQ   SEQUENCE   671 AA;  75931 MW;  976E2428D525A9B2 CRC64;
     MQPDMSLNVI KMKSSDFLES AELDSGGFGK VSLCFHRTQG LMIMKTVYKG PNCIEHNEAL
     LEEAKMMNRL RHSRVVKLLG VIIEEGKYSL VMEYMEKGNL MHVLKAEMST PLSVKGRIIL
     EIIEGMCYLH GKGVIHKDLK PENILVDNDF HIKIADLGLA SFKMWSKLNN EEHNELREVD
     GTAKKNGGTL YYMAPEHLND VNAKPTEKSD VYSFAVVLWA IFANKEPYEN AICEQQLIMC
     IKSGNRPDVD DITEYCPREI ISLMKLCWEA NPEARPTFPG IEEKFRPFYL SQLEESVEED
     VKSLKKEYSN ENAVVKRMQS LQLDCVAVPS SRSNSATEQP GSLHSSQGLG MGPVEESWFA
     PSLEHPQEEN EPSLQSKLQD EANYHLYGSR MDRQTKQQPR QNVAYNREEE RRRRVSHDPF
     AQQRPYENFQ NTEGKGTAYS SAASHGNAVH QPSGLTSQPQ VLYQNNGLYS SHGFGTRPLD
     PGTAGPRVWY RPIPSHMPSL HNIPVPETNY LGNTPTMPFS SLPPTDESIK YTIYNSTGIQ
     IGAYNYMEIG GTSSSLLDST NTNFKEEPAA KYQAIFDNTT SLTDKHLDPI RENLGKHWKN
     CARKLGFTQS QIDEIDHDYE RDGLKEKVYQ MLQKWVMREG IKGATVGKLA QALHQCSRID
     LLSSLIYVSQ N
//
